David A. Siegel Jounce Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.9 - $1.85 $299,430 - $615,495	-332,700 Reduced 87.44%	47,800 $88,000
Q4 2022 Feb 14, 2023	BUY	$0.64 - $1.99 $61,888 - $192,433	96,700 Added 34.07%	380,500 $422,000
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $100,191 - $180,564	-36,700 Reduced 11.45%	283,800 $664,000
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $16,800 - $46,020	-6,000 Reduced 1.84%	320,500 $971,000
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $1.2 Million - $1.7 Million	-199,000 Reduced 37.87%	326,500 $2.22 Million
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $1.06 Million - $1.44 Million	149,000 Added 39.58%	525,500 $4.39 Million
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $800,856 - $1.39 Million	158,900 Added 73.02%	376,500 $2.8 Million
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $886,984 - $1.44 Million	134,800 Added 162.8%	217,600 $1.48 Million
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $557,244 - $1.15 Million	82,800 New	82,800 $850,000
Q3 2020 Nov 16, 2020	SELL	$4.58 - $10.95 $115,874 - $277,035	-25,300 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$4.17 - $7.58 $100,497 - $182,678	-24,100 Reduced 48.79%	25,300 $175,000
Q1 2020 May 15, 2020	SELL	$2.91 - $8.7 $199,917 - $597,690	-68,700 Reduced 58.17%	49,400 $235,000
Q4 2019 Feb 14, 2020	SELL	$2.81 - $9.21 $64,068 - $209,988	-22,800 Reduced 16.18%	118,100 $1.03 Million
Q3 2019 Nov 14, 2019	SELL	$3.33 - $4.93 $36,630 - $54,230	-11,000 Reduced 7.24%	140,900 $469,000
Q2 2019 Aug 14, 2019	SELL	$4.3 - $6.73 $180,170 - $281,987	-41,900 Reduced 21.62%	151,900 $752,000
Q1 2019 May 15, 2019	SELL	$3.43 - $6.87 $252,448 - $505,632	-73,600 Reduced 27.52%	193,800 $1.2 Million
Q4 2018 Feb 14, 2019	BUY	$2.69 - $6.71 $160,593 - $400,587	59,700 Added 28.74%	267,400 $901,000
Q3 2018 Nov 14, 2018	BUY	$6.5 - $8.37 $839,800 - $1.08 Million	129,200 Added 164.59%	207,700 $1.35 Million
Q2 2018 Aug 14, 2018	BUY	$7.27 - $21.88 $570,695 - $1.72 Million	78,500 New	78,500 $601,000

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account